A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Muhtasari wa habari
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Fuatilia habari za hivi karibuni kutoka kwa wachapishaji wanaoaminika pamoja na muhtasari mfupi. Fungua chanzo asili kwa maelezo.